HIV drugs News and Research

RSS

Allocating HIV drugs to cities prevents the greatest number of infections

The most effective way to control the AIDS pandemic in hard-hit South Africa would be to concentrate the allocation of scarce antiretroviral drugs in urban areas.

12 Sep 2006

South Africa's AIDS policy 'comical'

The South African government came under harsh criticism over its AIDS policy at the close of the 16th International AIDS Conference in Toronto, Canada.

20 Aug 2006

1.65 million worldwide now receiving antiretrovirals

The number of people in sub-Saharan Africa with access to antiretroviral drugs has increased tenfold in three years, and 1.65 million people in low- and middle-income countries were receiving the drugs by the end of June.

17 Aug 2006

Bill Gates says protecting against HIV/AIDS can't be left to men

Microsoft founder Bill Gates says all the money in the world will not conquer HIV/AIDS unless more progress is made in preventing new infections. Gates says women and other high-risk groups must be given the ability to protect themselves.

14 Aug 2006

FDA approves Atripla for the treatment of HIV-1 infection in adults

Bristol-Myers Squibb Company and Gilead Sciences have announced the U.S. Food and Drug Administration (FDA) has granted approval of Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV-1 infection in adults.

13 Jul 2006

Most Americans don't know about Health Savings Accounts

A new nationally representative poll from the Kaiser Family Foundation examines what the public took away from President Bush’s State of the Union address, finding that the health messages in the speech have yet to register with most Americans.

16 Feb 2006

Unorthodox vaccine could one day help to prevent or control HIV infection

Researchers at Baylor College of Medicine (BCM) in Houston have reason to believe their unorthodox vaccine could one day help to prevent or control HIV infection, according to a study published in today's edition of Public Library of Science Medicine.

6 Jan 2006

United Kingdom has among the highest reported rates of primary resistance to HIV drugs worldwide

Those infected with HIV in the UK have one of the highest rates of resistance to anti-HIV drugs of anywhere in the world, prompting fears of a second wave epidemic of resistant virus, a new study claims in the British Medical Journal (BMJ).

26 Nov 2005

Diagnostics test for monitoring anti-HIV drugs hits European market

The test has been acquired by Delphic Europe - a diagnostics products provider - which will develop it in conjunction with viral resistance testing for market on the continent. The service was created by Professor David Back, Dr Saye Khoo and a team in the School of Biomedical Science and is currently used to analyse blood samples from patients with HIV across the UK in order to identify the correct dosage of medicine for individual patients.

7 Nov 2005

Survival rate of HIV-infected patients in India has risen in response to a 20-fold drop in the price of antiretroviral therapy

Many of the more than 5 million HIV-infected people living in India have been unable to obtain treatment due to the high cost. With the introduction of generic ART into India in 2000, the price of HIV drugs fell from $778 per month to $100 per month, and eventually declined even further to just $33 per month in 2003.

19 Oct 2005

No shred of evidence that HIV-positive men who lose fat in their legs reciprocally gain fat in their bellies

There is no syndrome that causes increased belly fat and decreased facial and limb fat among HIV-positive men who take antiretroviral drugs, according to a study by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

13 Oct 2005

Data show that HIV-infected older people not taking HAART have double the risk of death

HIV is often regarded as a disease of young people, due to its status as a drug-related or sexually transmitted disease. However, the number of people over age 50 who are infected with HIV is significant--and growing--according to an article in the Sept. 15 issue of Clinical Infectious Diseases, now available online.

30 Aug 2005

Analysis of the Phase I/II clinical trial of HIV drug candidate PA-457

V.I. Technologies (Vitex) and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil.

26 Jul 2005

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

19 Jul 2005

Thousands to be screened for affects from Teflon

After a federal scientific review panel said the chemical used to make teflon is "likely" to be carcinogenic to humans, tens of thousands of Ohio and West Virginia residents could be tested over the next year, to determine if their health has been affected by drinking water containing a chemical used to make the nonstick substance.

11 Jul 2005

HIV/AIDS drugs may also be effective against malaria

Researchers at The Queensland Institute of Medical Research (QIMR) have found that drugs used to treat HIV Aids may also be effective against the biggest killer in the world - malaria.

2 Jun 2005

Indian drug company Ranbaxy gains FDA approval for HIV drug

Indian drug company Ranbaxy Laboratories has this week become the first Indian drug company to gain regulatory approval for a generic anti-HIV drug.

2 Jun 2005

FDA recommends approval of the investigational anti-HIV drug tipranavir

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee recommended the approval of the investigational anti-HIV drug tipranavir (11-3). Tipranavir is a non-peptidic protease inhibitor that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents.

20 May 2005

Roche to discontinue the sale and distribution of Fortovase (saquinavir)

Roche announced today that it has decided to discontinue the sale and distribution of Fortovase (saquinavir), as clinical demand for the drug has declined significantly due to the availability of a new formulation of Invirase (saquinavir mesylate), which increasingly has become the preferred formulation of saquinavir.

18 May 2005

19 primary schoolchildren on HIV drugs after prank with needle

After an 8-year-old girl pricked her schoolmates with her mother's diabetes-testing needle nineteen primary school students have had to be been placed on drugs to fight HIV because one child in a group of nineteen was discovered to be HIV positive.

1 May 2005